PLRZ

6-K - Polyrizon Ltd. (0001893645) (Filer)

6-K - Polyrizon Ltd. (0001893645) (Filer)

Raanana, Israel, May 13, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the signing of its first Clinical Trial Agreement (CTA) with a U.S.-based clinical research site specializing in allergy studies, marking a key milestone toward the initiation of its clinical program for the NASARIXTM (PL-14) Allergy Blocker. The clinical site, located in Texas, will serve as the first participating center in Polyrizon's planned multi-center study evaluating the safety, tolerability, and efficacy of the NASARIXTM Allergy Blocker in patients wit

In light of the growing challenges posed by emerging respiratory threats, including recent Hantavirus, Polyrizon is advancing a biophysical barrier technology that may offer immediate, non-specific defense at the nasal gatewayHONG KONG, May 11, 2026 /PRNewswire/ -- Recent World Health Organization reports of Hantavirus clusters, including clusters of severe acute respiratory illness, have once again served as a stark reminder: the next major viral threat is never far away. Whether it is Hantavirus, a novel coronavirus variant, or an unexpected influenza strain, the pattern is consistent. Outbreaks emerge quickly, and the window for effective intervention is narrow. In these critical early we

EFFECT - Polyrizon Ltd. (0001893645) (Filer)

6-K - Polyrizon Ltd. (0001893645) (Filer)

Raanana, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the submission of amended claims in its U.S. patent application for its proprietary intranasal drug delivery platform. The amended claims expand the scope of protection of the Company's technology to include not only the core mucoadhesive composition, but also drug delivery systems and methods of use, which are designed to enhance the effectiveness of medications by increasing their residence time and ensuring close contact with mucosal tissues. This developmen

F-1/A - Polyrizon Ltd. (0001893645) (Filer)

SCHEDULE 13G - Polyrizon Ltd. (0001893645) (Subject)

6-K - Polyrizon Ltd. (0001893645) (Filer)

Raanana, Israel, April 27, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the filing of a divisional patent application with the Europe Patent Office for its Trap & Target (T&T) platform technology. This application focuses exclusively on protecting the Company's advanced intranasal drug delivery system, which is designed to enhance the effectiveness of medications by increasing their residence time and ensuring close contact with mucosal tissues and aligns with the Company's recently announced U.S. patent application which encompass

D - Polyrizon Ltd. (0001893645) (Filer)

F-1 - Polyrizon Ltd. (0001893645) (Filer)

6-K - Polyrizon Ltd. (0001893645) (Filer)

424B5 - Polyrizon Ltd. (0001893645) (Filer)

RAANANA, ISRAEL, April 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced the closing of its previously announced registered direct offering and concurrent private placement with a single institutional investor. The Company issued Ordinary Shares and pre-funded warrants in a registered direct offering. In a concurrent private placement, the Company also issued to the same investor pre-funded and investor warrants. Aggregate gross proceeds to the Company from both transactions were approximately $3.5 million. The transactions closed on April 8, 2026. The transacti

RAANANA, ISRAEL, April 07, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that it has entered into definitive agreements with a single institutional investor for the purchase and sale of its Ordinary Shares and pre-funded warrants in a registered direct offering. In a concurrent private placement, the Company also agreed to sell to the same investor pre-funded and investor warrants. Aggregate gross proceeds to the Company from both transactions are expected to be approximately $3.5 million. The transactions consisted of the sale of 388,888 Units (or Pre-Funded Uni

4 - Polyrizon Ltd. (0001893645) (Issuer)

4 - Polyrizon Ltd. (0001893645) (Issuer)

4 - Polyrizon Ltd. (0001893645) (Issuer)

4 - Polyrizon Ltd. (0001893645) (Issuer)

4 - Polyrizon Ltd. (0001893645) (Issuer)

4 - Polyrizon Ltd. (0001893645) (Issuer)

20-F/A - Polyrizon Ltd. (0001893645) (Filer)

Raanana, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon" or the "Company"), a pre-clinical-stage biotechnology company developing intranasal protective solutions, provided 2025 and recent a business update. "Polyrizon has delivered significant progress across its innovative nasal programs, including key regulatory advancements with the FDA, preparation for potential human clinical trials, and valuable medical collaborations, all powered by a strong cash position and a debt-free balance sheet," said Tomer Izraeli, chief executive officer of Polyrizon. Key Highlights of Polyrizon's Achievements in 2025 and Recent Highlights: As of December 31, 2025, t